ライフサイエンスコーパス: initial dose

1 pled again 7 days later (196 hours after the initial dose).

2 e considered for those not responding to the initial dose.

3 ee further doses at 4, 24 and 48 h after the initial dose.

4 relative to placebo but were limited to the initial dose.

5 rmacokinetic studies were performed with the initial dose.

6 rmacokinetic studies were performed with the initial dose.

7 of a drug produce greater responses than the initial dose.

8 to a lesser degree than that seen after the initial dose.

9 [3.1-8.2] ng/mL) (P<0.0001), despite similar initial doses.

10 ng a 93.3% tumor inhibition rate 12days post initial dosing.

11 f the first 24-h heartburn-free period after initial dosing.

12 Arm 1: prolonged-release tacrolimus (initial dose 0.2mg/kg/day); Arm 2: prolonged-release tac

13 ly x 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly).

14 ly, together with octreotide subcutaneously: initial dose 100 mug thrice daily and up to 200 mug thri

15 trial comparing oral mycophenolate mofetil (initial dose, 1000 mg per day, increased to 3000 mg per

16 tudy to identify a safe dose of rilotumumab (initial dose 15 mg/kg intravenously on day 1) plus ECX (

17 High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter) or standard-dose

18 s via subcutaneously implanted osmotic pump (initial dose 2.0 mg/kg/day, free base).

19 b (6 mg/kg once every 2 weeks) or cetuximab (initial dose 400 mg/m(2); 250 mg/m(2) once a week therea

20 were randomized to receive CsA (19 patients, initial doses 5 mg/kg/d) or matched placebo (20 patients

21 Two years after initial dosing, 571 patients (76.7%) remained on therapy

22 0% of the patients had been placed on excess initial doses according to the 2011 guidelines, and 47%

23 7% of the patients had been placed on excess initial doses according to the 2016 guidelines.

24 The initial doses administered were cisplatin 75 mg/m(2) eve

25 ntiation that is absolutely dependent on the initial dose and affinity of peptide presented to a naiv

26 avenous tyramine were assessed following the initial dose and after 1 and 2 weeks of drug administrat

27 in STAZN-treated rats, within 1-1.5 h of the initial dose and fell to a median score of 3 at 72 h, co

28 emain the primary treatment, but the optimal initial dose and tapering treatment regimens are unknown

29 Initial doses and schedules for cycle 1 consisted of OXP

30 Despite no difference in initial doses and time to reach 90% blockade or clinical

31 ous nanorod concentrations rose rapidly upon initial dosing and then fell to stable levels over the c

32 It was shown that this conservative initial dosing approach, which guarantees renal safety,

33 splant recipients with minimal risk when low initial doses are used (25 mug/kg; 1.5 mg if >/=60 kg) a

34 For small initial doses, as one would naturally expect to occur, t

35 ed platelet aggregation at 2 hours after the initial dose at 2 and 4 weeks was 15%, 8%, and 11% in th

36 Initial dose at the time of transplantation was 5 mg/kg

37 ) in 28-day-old rats tested 7 days after the initial dose, but did enhance the effects of a lower (0.

38 yses, in addition of smoking and epinephrine initial dose, cardiac troponin I (odds ratio 3.58 [2.03-

39 ged TAFs and inhibited tumor growth after an initial dose, chronic exposure to cisplatin NP led to el

40 d all patients have now been enrolled in the initial dose cohort (2 x 10(11) vg/kg).

41 rculation after 4h varies from 10% to 85% of initial dose, depending on the block copolymer.

42 /CT scans obtained at a median of 2 mo after initial dosing did not demonstrate significant changes i

43 Initial dose escalation in the UES group was followed by

44 In the initial dose-escalation phase 1 stage of the trial, pati

45 The initial dose-escalation phase established 25 mg twice da

46 In the initial dose-escalation phase, 25 patients with adenocar

47 Initial dose-escalation, build-up, and maintenance phase

48 tumors at doses of 116 mg/m(2)/d during the initial dose-finding period.

49 In an initial dose-finding study (substudy A), 6 women and 4 m

50 In initial dose-finding trials, pediatric-specific cohorts

51 A treatment regimen consisting of a high initial dose followed by an extended tapering of doses i

52 plus weekly doses of cetuximab: 400 mg/m(2) initial dose, followed by seven weekly doses at 250 mg/m

53 nded to be higher in association with higher initial doses (for initial doses <40 mg of prednisone pe

54 t was relapse-free efficacy at 6 months from initial dose (ie, clearance of initial infection without

55 in S6c induced transient vasodilation at the initial dose in rings from sham-treated rats but not lip

56 ock waves causes less tissue trauma when the initial dose is followed by a brief (3-4 min) pause in s

57 The initial dose level in arm 2 was above the MTD.

58 The initial dose level of cisplatin was 30 mg/m(2), escalate

59 In the low-GFR cohort, at the initial dose level using 12 mCi/kg of 131I-MIBG and redu

60 The initial dose level was 100 mg/m(2)/d with intrapatient d

61 mide once daily on days 1 to 21 (4 mg as the initial dose level), and dexamethasone (40 mg oral or IV

62 At the initial dose level, one of six patients developed febril

63 The initial dose levels were 2-CdA 0.1 mg/kg/d by continuous

64 n association with higher initial doses (for initial doses <40 mg of prednisone per day: RR, 3.23; 95

65 administered by subcutaneous injection at an initial dose of 0.05 mg per kilogram of body weight ever

66 ses of terlipressin (TERLI-BOL group) at the initial dose of 0.5 mg every 4 hours.

67 ated with oral risperidone for 4 weeks at an initial dose of 1 mg/day that was titrated as necessary

68 CDP571 at an initial dose of 10 or 20 mg/kg is safe and effective for

69 ovel oral anticoagulants such as dabigatran (initial dose of 110 mg within 1-4 h after surgery, follo

70 After an initial dose of 12 x 10(9) PFU/m(2), patients tolerated

71 These data suggest that an initial dose of 162 mg aspirin may be as effective as an

72 ntravenous infusion (TERLI-INF group) at the initial dose of 2 mg/day or intravenous boluses of terli

73 cipants were randomly assigned to receive an initial dose of 200,000 IU oral vitamin D3, then 200,000

74 Oral vitamin D3 in an initial dose of 200000 IU, followed a month later by mon

75 g/m2 followed by a continuous infusion at an initial dose of 30 mg/m2/d for 48 hours.

76 the burn, the conscious animals received an initial dose of 4 mL x kg(-1) HSD (n = 6) or normal sali

77 6.5 mmol per liter received patiromer (at an initial dose of 4.2 g or 8.4 g twice a day) for 4 weeks

78 y plus weekly cetuximab (211 patients) at an initial dose of 400 mg per square meter of body-surface

79 ceived either pleconaril 200 mg twice daily (initial dose of 400 mg) or placebo for 7 days.

80 Patients were treated with cetuximab at an initial dose of 400 mg/m(2), followed by 250 mg/m(2) wee

81 Ponatinib was administered at an initial dose of 45 mg once daily.

82 iclovir was administered intravenously at an initial dose of 5 mg/kg/d and then increased to 10 mg/kg

83 aise the question of whether the recommended initial dose of 5-FU-based chemotherapy for women should

84 d to sertraline (n = 102) for 12 weeks at an initial dose of 50 mg/d (escalated to a maximum dose of

85 Four healthy patients received an initial dose of 500-mg azithromycin followed by 250-mg d

86 AML patients were treated with CEP-701 at an initial dose of 60 mg orally twice daily.

87 received 9.95 GBq 131I-MN-14 F(ab)2, for an initial dose of 656 cGy to critical organs, 8 received 9

88 ID/OCT group received midodrine orally at an initial dose of 7.5 mg thrice daily, with the dose incre

89 tients in two sequential cohorts received an initial dose of 7.5 or 9.4 mg of imetelstat per kilogram

90 d 4 to 6 weeks after chemoradiotherapy at an initial dose of 75 mg/m2.

91 Two to six hours after the initial dose of alpha-MPT, concentrations of alpha-MPT w

92 Even at 25% of the initial dose of amidine-oxime (i.e., a dose of 36 mumol/

93 schema for combination therapy such that an initial dose of Apo2L/TRAIL would precede administration

94 DTPA)(30)-enhanced MR imaging followed by an initial dose of bevacizumab or saline (as a control).

95 Patients received an initial dose of cetuximab (400 mg/m(2)) on day 1 of week

96 An initial dose of cetuximab 400 mg/m2 intravenously was ad

97 The initial dose of CPT-11 was 125 mg/m2 given as a weekly 9

98 Fourteen hours after receiving the initial dose of either pleconaril or placebo, subjects w

99 The corresponding recommended initial dose of FK506 for kidney transplant recipients i

100 The corresponding recommended initial dose of FK506 for kidney transplant recipients s

101 The initial dose of gemcitabine was 20 mg/m(2) by 30-minute

102 ients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remi

103 hildren received IIV followed by LAIV, 13 an initial dose of LAIV, and 11 a second dose of LAIV.

104 uenza viral strains were recovered after the initial dose of LAIV.

105 The initial dose of lenalidomide used (25 mg/d) was poorly t

106 ed by electroretinography 72 hours after the initial dose of methanol and after a 72-hour recovery pe

107 Tacrolimus in combination with an initial dose of MMF 2 g/day is a very effective and safe

108 The mean initial dose of MMF was 0.92 g/d (range, 0.5 to 2 g/d).

109 ted before and after in vivo exposure to the initial dose of OFA therapy in 25 patients undergoing th

110 For the induction dose of hypnotics and the initial dose of other drugs that have a fast onset of ef

111 The initial dose of paclitaxel was 170 mg/m2, and this was e

112 The initial dose of paclitaxel was 30 mg/m2 by 3-hour intrav

113 to estimate vaccine effectiveness (VE) of an initial dose of pH1N1 monovalent vaccine in children age

114 ion or immediately after reperfusion with an initial dose of PNU-101017 (30 mg/kg i.p.) or diazepam (

115 s because they are able to tolerate a higher initial dose of radiation.

116 d before and 4 hours after initiation of the initial dose of rituximab in 21 lymphoma subjects.

117 mL collagen was measured over time after the initial dose of study drug and at 1 and 2 weeks of chron

118 mL collagen was measured over time after the initial dose of study drug and at days 14 and 28 of long

119 ' self-reported pain within 5 minutes of the initial dose of sublingual or spray nitroglycerin.

120 y transplantation or retransplantation to an initial dose of tacrolimus BD 0.2 mg/kg per day (Arm 1;

121 nt >10 x 10(9) cells per L) could receive an initial dose of the immunoconjugate gemtuzumab ozogamici

122 The initial dose of vinorelbine 30 mg/m2 was administered as

123 oses of 3 mg/kg, 10 mg/kg, or 30/10 mg/kg (2 initial doses of 30 mg/kg, followed by 10 mg/kg) on days

124 A fifth cohort of two participants received initial doses of 900 mg.

125 nimals were inoculated intranasally with the initial doses of bacterial suspension.

126 We recommend that initial doses of CAF be computed according to actual bod

127 Febrile neutropenic patients should receive initial doses of empirical antibacterial therapy within

128 Corresponding initial doses of FK506 were 0.2, 0.3, and 0.4 mg/kg/day.

129 Corresponding initial doses of FK506 were 0.2, 0.3, or 0.4 mg(kg/day,

130 Initial doses of OKT3 are associated with a cytokine-ind

131 sequentially assigned to receive escalating initial doses of sirolimus (0.5-7.0 mg/m2/day), in addit

132 stinal adverse events with onset 2-5 h after initial doses of the vaccine, similar to those caused by

133 Our methodology involves the initial dosing of a chemical probe such as carbon monoxi

134 kin biopsies performed both before and after initial dosing of that patient revealed less fibrosis an

135 afety profile of sunitinib 50 mg once-daily (initial dose) on schedule 4-2 was manageable and efficac

136 12.2 +/- 3.9 kPa) over the 96 hrs after the initial dose (p = .021 by repeated-measures analysis of

137 These initial dosing patterns remained remarkably consistent u

138 In this initial, dose-ranging, 12-week study, treatment with rhv

139 both the initial 90Y femur activity and the initial dose rate from external 137Cs gamma rays with 5.

140 9-AC was infused over 72 hours at an initial dose rate of 40 microg/m2/h every 3 weeks with s

141 Initial dose rates ranging from 0.01-30 cGy/hr can be de

142 y decreasing dose rates of 137Cs gamma rays, initial dose rates required to achieve 37% survival were

143 Using the calibrated dosimeter, the initial dose rates to the marrow per unit of injected ac

144 Variant allele carriers received an initial dose reduction of >/= 50% followed by dose titra

145 and VKORC1 that suggest he might have a low initial dosing requirement for warfarin.

146 Using human monocyte cell line (THP-1), initial dose-response experiments were conducted to dete

147 ion of seizures, time to first seizure after initial dose stabilisation), and adverse events (inciden

148 In an initial dose-testing phase we found a Guanfacine dose th

149 days of standard-dose cetuximab (400 mg/m(2) initial dose, then 250 mg/m(2) per week) plus irinotecan

150 ng a kinetic model, we uncovered a nonlinear initial dose threshold that is dependent on the amount o

151 examination was performed 24 hours after the initial dose to enable calculation of the acute change i

152 toneal injection at doses ranging from 62.5 (initial dose) to 25 mg/kg.

153 The initial dose was 20 mCi and escalation was in 20-mCi inc

154 The initial dose was 25 mg, with subsequent escalations to 3

155 The initial dose was 300 mg orally in a single daily dose fo

156 The initial dose was 75 mg/m2 with G-CSF 5 micrograms/kg.

157 The initial dose was based on the average epoetin dose given

158 This initial dose was followed by a continuous apyrase infusi

159 nto hydrogels, a maximum of about 60% of the initial dose was released within 7days to 21days.

160 f the first 24-h heartburn-free period after initial dosing was 2.0 (+/- 2.2) days for Gaviscon(R) an

161 d failure risk ratio (weight-based v reduced initial doses) was 0.73 (95% confidence interval, 0.53 t

162 Initial doses were closely similar at admission for both

163 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg ev